A new understanding of how tumours exploit our nervous system is leading to new ways to treat cancer using familiar drugs ...

Daiichi Sankyo has announced the first subject dosing in the Phase III DESTINYEndometrial01 trial of Enhertu (trastuzumab ...

LOS ANGELES — Jay Harris, an ESPN "SportsCenter" anchor, has announced he will be missing from the program for about a month ...

The following is a summary of “Characteristics and role of surgery in nonagenarians with colorectal cancer: SEER database ...

In the DESTINY-Breast09 study, Enhertu (fam-trastuzumab deruxtecan-nxki) plus pertuzumab reduced the risk of disease ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

China’s National Medical Products Administration (NMPA) has approved Akeso's PD-1/CTLA-4 bispecific antibody, cadonilimab, to ...

Space infrastructure company Redwire Corporation has secured a contract from Aspera Biomedicines to carry out space-based ...

AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ( ...

New event focuses on private credit transaction origination, with dedicated one-on-one meeting opportunities for companies ...

The 2025 ASCO Annual Meeting is taking place in Chicago, US, from May 30 to June 3. Duality Bio (HKEX: 9606.HK) presented the ...